8-K: Heart Test Laboratories Receives Stay on Delisting, Awaits Nasdaq Hearing

Heart Test Laboratories has received a stay on its delisting from Nasdaq pending a hearing, following a reverse stock split aimed at regaining compliance.

Summary

• Heart Test Laboratories received a notice from Nasdaq on May 17, 2024, that its delisting has been stayed.
• This stay is pending a final decision by a Nasdaq Hearing Panel after the company's appeal.
• The company's appeal was triggered by a delisting notice due to the stock price falling below $0.10 for ten consecutive days.
• Heart Test Laboratories implemented a 1-for-100 reverse stock split on May 17, 2024, to address the low stock price.
• The company believes it has regained compliance with Nasdaq's Low Priced Stocks Rule and Minimum Bid Price Requirement.
• A hearing is scheduled for June 27, 2024, where the company will present its case.
• The company's stock and warrants will continue to trade on Nasdaq under the symbols HSCS and HSCSW, respectively, during the appeal process.
• There is no guarantee that the appeal will be successful or that the company will remain listed on Nasdaq.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the delisting notice and the uncertainty surrounding the appeal, although the stay provides a temporary reprieve.

Positives

• The delisting of Heart Test Laboratories has been temporarily stayed, allowing the company to remain listed on Nasdaq.
• The company has an opportunity to present its case at a hearing on June 27, 2024.
• The reverse stock split is intended to help the company regain compliance with Nasdaq listing requirements.

Negatives

• The company received a delisting notice from Nasdaq due to its low stock price.
• There is no guarantee that the company's appeal will be successful or that it will remain listed on Nasdaq.
• The company's stock price fell below $0.10 for at least ten consecutive trading days, triggering the delisting notice.

Risks

• There is a risk that the Nasdaq Hearing Panel will not rule in favor of the company.
• The company may not be able to maintain compliance with Nasdaq listing requirements even after the reverse stock split.
• The company's stock price may continue to be volatile.

Future Outlook

The company's future on Nasdaq depends on the outcome of the hearing on June 27, 2024, and its ability to maintain compliance with listing requirements.

Management Comments

• The Company intends to present information to show that the Company believes it has regained compliance with both the Low Priced Stocks Rule and the Minimum Bid Price Requirement.
• While the Company believes that it has regained compliance with the Low Priced Stocks Rule, the Minimum Bid Price Requirement and the other Nasdaq continued listing requirements, there can be no assurance that the Company's appeal will be successful or that the Company will otherwise be in compliance with the other Nasdaq listing rules or remain listed on Nasdaq.

Industry Context

This situation is not uncommon for companies facing low stock prices, and the reverse stock split is a typical measure to regain compliance with exchange listing requirements. Many small cap companies face similar challenges.

Comparison to Industry Standards

• Many small-cap companies listed on exchanges like Nasdaq face challenges in maintaining minimum bid prices.
• Reverse stock splits are a common strategy used by companies to avoid delisting.
• The outcome of the hearing will be critical for Heart Test Laboratories, as many companies in similar situations have been delisted.

Stakeholder Impact

• Shareholders face uncertainty regarding the company's future listing status.
• Employees may be concerned about the company's long-term viability.
• Customers and suppliers may be monitoring the situation for any potential impact on their relationships with the company.

Next Steps

• The company will attend a hearing with the Nasdaq Hearing Panel on June 27, 2024.
• The company will present information to demonstrate compliance with Nasdaq listing rules.
• The company will await the final written decision by the Nasdaq Hearing Panel.

Key Dates

Keywords

delisting, Nasdaq, reverse stock split, hearing, compliance, HSCS, HSCSW, minimum bid price, low priced stocks